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Available online 8 January 2016Background& aims: To study the origin of fat excess in the livers ofmorbidly obese (MO) individuals, we analysed
lipids and lipases in both plasma and liver and genes involved in lipid transport, or related with, in that organ.
Methods: Thirty-two MO patients were grouped according to the absence (healthy: DM−DL−) or presence of
comorbidities (dyslipidemic: DM−DL+; or dyslipidemic with type 2 diabetes: DM+DL+) before and one
year after gastric bypass.
Results: The livers of healthy, DL andDMpatients containedmore lipids (9.8, 9.5 and 13.7 times, respectively) than
those of control subjects. The genes implicated in liver lipid uptake, includingHL, LPL,VLDLr, and FAT/CD36, showed
increased expression compared with the controls. The expression of genes involved in lipid-related processes
outside of the liver, such as apoB, PPARα and PGC1α, CYP7a1 andHMGCR, was reduced in these patients compared
with the controls. PAI1 and TNFα gene expression in the diabetic livers was increased compared with the other
obese groups and control group. Increased steatosis and ﬁbrosis were also noted in the MO individuals.
Conclusions: Hepatic lipid parameters in MO patients change based on their comorbidities. The gene expression
and lipid levels after bariatric surgerywere less prominent in the diabetic patients. Lipid receptor overexpression
could enable the liver to capture circulating lipids, thus favouring the steatosis typically observed in diabetic and
dyslipidaemic MO individuals.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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NAFLD have been related to metabolic syndrome and obesity [5,6]. The
epidemic of obesity has increased the prevalence of NAFLD, and it is al-
ready the most common liver disorder in developed countries. Morbid
obese patients have a high proportion of NAFLD [7].The coexistence of
metabolic syndrome and NAFLD has made insulin resistance central to
the pathogenesis of these disorders. The metabolic consequence of in-
sulin resistance is impaired hepatic glucose output and abnormal lipid
handling. In the face of continued metabolic insults the normal hepatic
regulatory mechanism gets overwhelmed and fat accumulates in the
hepatocytes. The subsequent fate of steatotic hepatocytes depends on
the capacity of additional factors such as adipocytokines and toxicity in-
duced by the free fatty acids themselves to induce inﬂammatory re-
sponse [8]. NASH is characterised by hepatocyte injury, inﬂammation
and ﬁbrosis, which can lead to cirrhosis, liver failure and hepatocellular
carcinoma [9]. It is associatedwith increased serum levels of hepatic en-
zymes [10], the activities ofwhich are strongly inﬂuenced by the plasma
PAI1 levels in both hyper- and normolipidaemic subjects [11].
Furthermore, obese subjects exhibit increased liver lipoprotein
lipase (LPL) activity [12]. LPL is an extra-hepatic enzyme that limits up-
take of circulating TAGs into tissues. Hence, its activity could enable the
liver to accumulate circulating TAGs, leading to steatosis [12]. Moreover,
morbidly obese (MO) patients exhibit increased local hepatic lipase
(HL) activity and mRNA expression, favouring cholesterol uptake by
the liver and its re-exportation to steroidogenic organs [13].
It is unclear why some obese people develop IR and type 2 diabetes
mellitus (DM), whereas others with the same BMI do not [14,15]. How-
ever, the absence of DM or dyslipidaemia (DL) is not sufﬁcient to deﬁne
“healthy obesity”, at least in the context of the MO [16]. In fact, marked
deﬁciencies in several haematological parameters have been observed
in “theoretically healthy obese” individuals [16]. Additionally, patients
with dyslipidaemia and type 2 diabetes exhibit decreases in adipose tis-
sue lipase expression and activity, which are not observed in “healthy”
MO or normal-weight patients [17].
Finally, although surgery is considered the most effective treatment
for obesity, its effects on NAFLD and lipid metabolism are variable and
procedure dependent [18,19]. Following gastric bypass, important im-
provements in the lipid proﬁle and IR have been reported [12]. Howev-
er, the effects of surgery on lipid metabolism enzymatic activity in the
liver have not been studied in depth. Furthermore, whether differences
in surgery-induced alterations in liver function are dependent on the
presence or absence of comorbidities has not been assessed.
In this study, changes in lipid levels and lipase activities (LPL andHL)
in the liver and plasma were studied in “healthy” and unhealthy (those
with DL or both DM and DL) MO patients who underwent bariatric sur-
gery and received follow-up for 1 year during the weight loss period.
Additionally, the expression levels of genes related to lipid metabolism,
inﬂammation and oxidative stress were studied and correlated with
plasma and tissue liver injury markers.
2. Materials and methods
2.1. Patient selection and samples extraction
Thirty-two MO patients (23 women and 9 men) between 21 and
61 years of age who underwent Roux-en-Y gastric bypass (RYGBP) sur-
gery were enrolled and received follow-up at the Hospital de la Vall
d'Hebron in Barcelona, Catalonia, as described elsewhere [20]. The sub-
jects presented the necessary indications for bariatric surgery: BMI N40
or N35 kg/m2, with at least one comorbidity (including hypertension
(HTA), DM, DL, obstructive sleep apnoea, or weight-induced rheumato-
logic disease). The diagnostic criteria used for DM, HTA, and metabolic
syndrome are detailed in the National Cholesterol Education Program
[21]. None of the diabetic or dyslipidaemic patients were being treated
with anti-diabetic or anti-hyperlipidaemic drugs, respectively, before
or after bariatric surgery. The study protocol was accepted by thehospital ethics committee. The protocol conformed to the Declaration
of Helsinki, and all subjects provided written informed consent to
participate.
Patients were considered to be “healthy” morbidly obese patients
when we apply the most restrictive criteria of Wildman et al. [22].
Thus for DM, the threshold was for fasting plasma glucose ≥100 mg/dL
or medically diagnosed DM; the criteria for HTA was: systolic and dia-
stolic blood pressure (SBP and DBP, respectively), SBP ≥ 130 mmHg
and DBP ≥ 85 mmHg, and the criteria for DL was: TG ≥ 150 mg/dL,
cLDL ≥110 mg/dL and cHDL b40 and 50 mg/dL for men and women,
respectively, or medically diagnosed DL.
The patients were divided into three groups according to their hos-
pital medical diagnosis of DL and/or DM as follows: 10 “healthy”
obese patients (DM−DL− group, 6 women and 4 men); 15 obese pa-
tients with DL (DM−DL+ group, 11 women and 4 men); and 7 obese
patients with DL and DM (DM+DL+ group, 6 women and 1 man).
Blood sampleswere obtained under fasting conditions between 8:00
and 10:00 a.m. on the day of RYGBP and at 1, 6 and 12months after sur-
gery (labelled 1, 6 and 12M in the Graphs and Tables). An index biopsy
from 24 patients was taken at the time of bariatric surgery (Roux-en-Y
gastric bypass), with a Hepaﬁx needle. In those patients a follow-up bi-
opsy was obtained 16.3 ± 3 months (range: 12–18 months) after bar-
iatric surgery as a percutaneous biopsy using a same kind of needle.
All biopsieswere at least 2 cm in length and contained at least eight por-
tal tracts. The anaesthetic procedureswere standardised in both elective
surgery and biopsy procedures. In biopsy procedures, 1% Scandicainwas
used. Epinephrinewas avoided. Liver sampleswere quicklyminced, fro-
zen in liquid nitrogen, and stored at−80 °C for further analysis.
The control group (labelled as C in the Graphs and Tables) included
22 euthyroid, normal-weight, normotensive, non-diabetic patients (12-
h fast)whounderwent elective cholecystectomy at the same time that a
blood sample was obtained. Liver biopsy was obtained from only seven
of these patients.2.2. Anthropometric and body composition measurements
Body weight, height, and waist circumference were measured
according to standardised procedures [23]. The body fat percentage
and amounts of total, subcutaneous and visceral fat were calculated as
described previously [24].2.3. Measurements of plasma and liver parameters
The leptin, ghrelin, adiponectin, insulin, glucose, homeostasis model
assessment of insulin resistance (HOMA-IR), and plasma and liver lipid
(TAG, PL, TC, cLDL, cHDL andNEFA) levelswere determined as previous-
ly described [25,26]. DNA in the liver biopsies was quantiﬁed via the
ﬂuorimetric method [27]. The AST, ALT and GGT levels were measured
enzymatically at the hospital's routine chemistry laboratory. The alka-
line phosphatase and bilirubin levels were measured using a Beckman
Coulter AU5400/2700 analyser (Brea, USA). The glycerol level was
determined via the enzymatic method [28]. The CRP level was deter-
mined using an immunometric/turbidimetric assay performed with a
METROLAB 2300 autoanalyser (RAL, Laboratory Techniques, Spain).
The PAI1 level was measured by enzyme-linked immunosorbent assay
(ELISA) [29]. Ketone body (KB) levels were indirectly determined by
quantiﬁcation of b-hydroxybutyrate via an enzymatic method [30].2.4. Liver lipid extraction
We used a method for extracting a small amount of tissue that
has been previously described by our group [31]. Lipid extracts were
analysed as described [12].
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Lipase assays involving the use of TAGs containing radiolabeled acyl
chains are highly speciﬁc and sensitive [32]. In our study, the LPL andHL
activities were assessed as described previously [33,34] with minor
modiﬁcations [13].
2.6. Histological analysis of liver
Haematoxylin-eosin- and trichrome-stained samples from all liver
biopsies (obtained pre- and post-surgery) were reviewed by a patholo-
gist without knowledge of the clinical data. The samples were classiﬁed
according to the criteria of Brunt [35]. The following parameters
were graded in thebiopsies: a) steatosis: 0–3; b) hepatocyte ballooning:
0–3; c) lobular inﬂammation: 0–3; and d) portal inﬂammation with or
without different ﬁbrosis stages: 0–4.
2.7. Total RNA and cDNA preparation and PCR analyses
Total RNA was extracted from 15 to 25 mg of human liver biopsy
sample with Tripure Isolation Reagent (Roche, USA). First-strand com-
plementary DNA (cDNA) was synthesised from 0.4 μg total RNA using
random primers and TaqMan high-capacity cDNA reverse transcription
reagents (Applied Biosystems, USA). To perform real-time PCR, TaqMan
low-density array cardswere used (Applied Biosystems, USA). A 100-ng
aliquot of cDNA was mixed with TaqMan Gene Expression MasterMix
(Applied Biosystems, USA) and applied to the card. Gene-speciﬁc
primers and probemixtures were subsequently placed on the card. Rel-
ativemRNA levelswere evaluated using theΔΔCtmethod. Details about
the genes used in this study are provided in Supplemental Table 1.
2.8. Statistical analysis
The results are reported as the mean ± SEM. Signiﬁcant differences
among the mean values for the control (C), obese (OB) and 12 months
(M) (in some cases, 1 M and 6 M were added) after surgery (weight
loss) groups were assessed using the non-parametric Kruskal–Wallis
test, and individual comparisons were made using Dunn's post-test.
Signiﬁcant differences between the “healthy”MO (DM−DL−), dyslip-
idaemic (DM−DL+) and diabetic and dyslipidaemic (DM+DL+)
individuals at different times after surgery (weight loss effect) were
assessed by two-way ANOVA (comorbidities and surgery effect, respec-
tively) and the Bonferroni post-test. For histological comparisons
pre-surgery and post-surgery, paired t-tests were used and conﬁrmed
with Wilcoxon signed rank tests. Correlations between independent
variables were determined by Pearson's correlation coefﬁcient. Statisti-
cal comparisons were considered signiﬁcant at a p b 0.05.
All statistical analyseswere computedusingGraphPadPrismversion
5.0 software for Windows (GraphPad Software, San Diego CA, USA,
www.graphpad.com).
3. Results
3.1. Clinical characteristics of patients (Table 1)
The “healthy” obese patients exhibited 13 and 17.5% more total and
subcutaneous fat, respectively, comparedwith the DM+DL+obese in-
dividuals. Additionally, the DM−DL+ and DM+DL+ individuals had
respectively 69 and 61% more leptin, 72 and 69% more TAG, 41 and
27% more TC, 44 and 26% more cLDL, 17 and 19% more apoA1 and 33%
more apoB than the “healthy” obese individuals. The “healthy” obese
group exhibited an HOMA-IR level (6.92 ± 1.37 au) compared with
the DL group. The leptin/adiponectin ratios (IR marker) [36] were
0.83, 2.81, 3.59 and 3.59 in the control, “healthy”, dyslipidaemic and
diabetic obese individuals, respectively. One year after surgery, these
ratios were decreased to 0.26, 0.48 and 0.44, in the “healthy”,dyslipidaemic and diabetic obese individuals, respectively. Reductions
in both body weight (53, 47 and 44 kg for the “healthy”, DM−DL+
and DM+DL+groups, respectively) and BMI (19, 18 and 17 points, re-
spectively) were observed at one year after surgery. Additionally, the fat
content, waist circumference, and leptin, TAG, NEFA, TC, cLDL (apoBwas
also reduced), insulin, glucose, CRP, PAI1 and HOMA-IR levels were re-
duced. The adiponectin and ghrelin levels increased signiﬁcantly and
proportionally to the weight loss, and the lipid proﬁle improved, with
increases in cHDL and ApoA1. It should be noted that some parameters
such as TC, LDL, HDL and apo A1, after a year of surgery, are higher, but
did not become signiﬁcant difference, in the DM+DL+ group than in
the DM−DL+ group and, in this higher than in the DM−DL.
3.2. Biochemical liver parameters (Table 2)
The amount of lipids per cell was 10-fold in the “healthy” and dyslip-
idaemic obese individuals and 14-fold in the DM patients compared
with the controls. These amounts were proportional with the observed
plasma lipid level. The “healthy” obese patients exhibited 2-fold more
LPL andHL activities, between 7- and 10-fold in the TAG and lipid levels,
an 18-fold in the PL level, a 28-fold in TC and 30-fold in the NEFA and
CRP levels than control individuals. These parameters are similar to
those observed in the patients with dyslipidaemia, but the levels were
even higher in the obese individuals with DM. The increased LPL activity
in both the “healthy” and dyslipidaemic individuals was directly related
with increased liver enzyme mRNA levels. The increased HL activity in
the obese individuals was related to increases in both the TC and PL
levels in the liver.
3.3. Other plasma parameters related to hepatic metabolism (Table 3)
The “healthy”, DL and DM obese subjects exhibited 3.3-, 3.5- and
3.6–fold increases, respectively, in the glycerol and NEFA levels com-
pared with the controls with similar plasma proﬁles after surgery, sec-
ondary to adipose tissue TAG hydrolysis via hormone-sensitive lipase
(HSL) [24]. The glycerol and NEFA levels remained elevated at one
year after surgery given that HSL activity remained elevated, as we
have recently demonstrated [24]. The concentration of plasma KBs
was increased in the obese individuals at one month after surgery.
Moreover, the ketotic ratio (KB:NEFA), a non-invasive in vivo measure-
ment that provides insights into the direct ketotic activities of hormones
independent of their lipolytic effects [37], was also increased after one
month but returned to baseline at one year after bariatric surgery.
3.4. Histological liver results (Tables 4 and 5)
Diabetic MO patients exhibited clear increasing trends in the levels
of the assessed parameters, as measured by Brunt's index [35], com-
pared with the “healthy” and dyslipidaemic individuals, especially
steatosis and ﬁbrosis (Table 4). The decrease in liver damage following
bariatric surgery was signiﬁcant in all cases; however, this decrease
was considerably more pronounced in the patients with steatosis and
ballooning. In general, there were a larger proportion of non-responder
with respect to liver histology in DM−DL+ and DM+DL+ groups
than in “healthy” DM−DL− group following bariatric surgery. Table 5
shows scoring for the grade and stage of NASH in liver biopsies
performed at surgery and during follow-up. None of the secondbiopsies
revealed progression of grade or stage of liver disease. One year after the
surgery, only 2 patients (one in DM−DL+ group and 1 more in
DM+DL+ group) presented NAFLD (pre- vs. post-surgery, p b 0.0001).
Fibrosis (Table 5) score improved overall by two stages in 1 patient
with DM−DL+ and by one stage in 9 patients (4 patients in
DM−DL− group, 2 in DM−DL+ and 3 in DM+DL+). In 13 patients,
ﬁbrosis remained stable and we didn't observe any patient with wors-
ening of liver ﬁbrosis (Table 5).
Table 1
Clinical and metabolic characteristics of morbidly obese patients in each group before and after bariatric surgery.
PLASMA Anova-2, p value
Parameters Control (n = 22) Time DM−DL− (n = 10) DM−DL+ (n = 15) DM+DL+ (n = 7) Comorbidities effect Surgery effect
Body weight (Kg) – OB 136.7 ± 6.4 131.8 ± 4.7 118.0 ± 7.4 0.0004 b0.0001
12 M 83.8 ± 4.9 84.8 ± 5.3 74.4 ± 4.4
p b 0.0001 p b 0.0001 p b 0.0001
BMI (Kg/m2) – OB 49.4 ± 1.9 49.8 ± 1.3 47.37 ± 1.24 ns b0.0001
12 M 30.9 ± 1.7ooo 31.7 ± 1.5ooo 30.1 ± 1.6ooo
p b 0.0001 p b 0.0001 p b 0.0001
Total fat (Kg) – OB 81.2 ± 5.8 82.3 ± 4.6 71.0 ± 4.6 0.0103 b0.0001
12 M 35.1 ± 3.3ooo 37.7 ± 3.9ooo 31.0 ± 3.2ooo
p b 0.0001 p b 0.0001 p b 0.0001
SAT (Kg) – OB 62.4 ± 5.3 60.5 ± 4.3 51.5 ± 4.0 ns b0.0001
12 M 30.3 ± 5.0oo 27.2 ± 3.7ooo 29.1 ± 3.1o
p = 0.0006 p = 0.0001 p = 0.0069
VAT (Kg) – OB 21.3 ± 2.4 22.6 ± 2.4 19.4 ± 2.5 ns 0.0001
12 M 6.7 ± 1.2oo 9.4 ± 1.7oo 8.3 ± 2.3o
p = 0.0002 p = 0.0048 p = 0.0207
Waist (cm) – OB 134.8 ± 3.9 136.7 ± 3.7 138.1 ± 5.0 ns b0.0001
12 M 95.2 ± 4.0ooo 99.0 ± 4.3ooo 102.7 ± 9.5o
p b 0.0001 p b 0.0001 p = 0.0068
Leptin (ng/mL pl.) 15.0 ± 0.9 OB 26.1 ± 5.7 44.1 ± 6.9&,cc 42.0 ± 6.8&,c 0.0024 b0.0001
12 M 4.8 ± 1.2oo,ccc 10.7 ± 2.6ooo 7.9 ± 2.7ooo,c
p = 0.0040 p b 0.0001 p = 0.0002
Ghrelin (pg/mL pl.) 132.0 ± 0.3 OB 83.5 ± 13.3cc 48.7 ± 5.8&,ccc 86.0 ± 16.8+,c ns 0.01
12 M 124.9 ± 23.9o 122.5 ± 22.5oo 122.4 ± 21.6o
p = 0.0141 p = 0.0005 p = ns
Adiponectin (μg/mL pl.) 18.1 ± 2.3 OB 9.3 ± 1.1ccc 12.3 ± 1.7c 11.7 ± 3.0 ns b0.0001
12 M 18.6 ± 3.2 22.3 ± 2.5o 17.9 ± 1.9
p = ns p = 0.0150 p = ns
TAG (mg/dL pl.) 89.0 ± 9.0 OB 103.4 ± 8.2 177.6 ± 33.9&,c 174.8 ± 14.5&&,ccc b0.0001 b0.0001
12 M 78.9 ± 11.2 99.8 ± 7.5o 102.3 ± 13.9
p = 0.0083 p = 00.111 p = 0.0334
NEFA (mM pl.) 0.32 ± 0 OB 0.55 ± 0.07c 0.60 ± 0.05ccc 0.60 ± 0.09c ns b0.0001
12 M 0.42 ± 0.05 0.56 ± 0.07cc 0.55 ± 0.07c
p = 0.0003 p b 0.0001 p = ns
TC (mg/dL) 164.0 ± 3.0 OB 174.3 ± 5.2 245.4 ± 18.2&&&,ccc 220.7 ± 9.1&&,ccc b0.0001 b0.0001
12 M 132.9 ± 10.2oo,c 142.1 ± 18.2o 175.0 ± 5.5o
p b 0.0001 p = 0.0183 p = 0.0158
cLDL (mg/dL) 105.0 ± 4.0 OB 109.2 ± 3.4 157.1 ± 10.9&&,ccc 137.5 ± 7.2&,ccc b0.0001 b0.0001
12 M 75.0 ± 7.1oo,c 96.9 ± 6.1o 98.5 ± 5.0o
p b 0.0001 p = 0.0236 p = 0.0319
cHDL (mg/dL pl.) 74.0 ± 4.0 OB 44.7 ± 2.1ccc 53.0 ± 5.3cc 48.2 ± 3.4ccc 0.0002 b0.0001
12 M 42.4 ± 2.8ccc 51.5 ± 2.8ccc 56.0 ± 2.2ccc
p = 0.0001 p = 0.0019 p = 0.0091
apoA1 (mg/dL pl.) 197.5 ± 6.4 OB 167.5 ± 4.1cc 195.4 ± 8.5 198.5 ± 8.4 0.0003 b0.0002
12 M 159.1 ± 6.5**,ccc 197.4 ± 10.6 207.9 ± 9.0
p b 0.0001 p b 0.0001 p b 0.0001
apoB (mg/dL pl.) 68.4 ± 4.9 OB 69.6 ± 1.3 92.7 ± 4.3ccc 92.4 ± 6.4ccc 0.0004 b0.0003
12 M 52.1 ± 2.7oo,cc 70.6 ± 4.4** 68.7 ± 3.0**
p = 0.0003 p = ns p = ns
Insulin (UI/L pl.) 11.0 ± 1.0 OB 27.7 ± 5.2cc 22.8 ± 5.3 23.4 ± 4.0c ns b0.0001
12 M 9.2 ± 1.4oo 7.8 ± 1.1oo,c 8.7 ± 1.5o
p = 0.0017 p = 0.0028 p = 00.109
Glucose (mg/dL pl.) 72.0 ± 2.1 OB 99.8 ± 2.9ccc 104.0 ± 4.4&&&,ccc 164.1 ± 22.3&&,cc b0.0001 b0.0001
12 M 83.9 ± 2.5oo,cc 87.7 ± 2.1oo,ccc 95.0 ± 6.1o,cc
p = 0.0007 p = 0.0032 p = 0.0079
HOMA (a.u.) 2.0 ± 0.1 OB 6.9 ± 1.4cc 5.7 ± 1.5 10.2 ± 2.8c ns b0.0001
12 M 1.8 ± 0.5oo 1.6 ± 0.3oo 2.2 ± 0.6o
p = 0.0023 p = 0.0018 p = 0.0121
CRP (mg/L pl.) 6.9 ± 0.9 OB 18.0 ± 2.6cc 22.4 ± 2.9ccc 21.9 ± 4.0cc 0.0041 b0.0001
12 M 3.1 ± 0.8ooo,cc 5.3 ± 1.1ooo 3.3 ± 1.0oo,c
p = 0.0002 p b 0.0001 p = 0.0004
PAI1 (ng/mL pl.) 76.2 ± 11.0 OB 156.8 ± 28.1c 158.2 ± 24.5c 160.0 ± 40.4 ns b0.0001
12 M 39.3 ± 11.8o,c 32.0 ± 7.7ooo,cc 34.5 ± 12.3o,c
p = 0.0066 p = 0.0006 p = 0.0331
The data are expressed as themeans± SEM. Abbreviations: SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; TAG, triacylglycerides; NEFA, non-esteriﬁed fatty acid; TC, total
cholesterol; cHDL, HDL cholesterol; cLDL, LDL cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; a.u., arbitrary units; CRP, C-reactive protein; PAI1, plasminogen
activator inhibitor 1; OB and 12 M, OB− and 12 M−, and OB+ and 12 M+, obese and 12 months after surgery in the DM−DL−, DM−DL+ and DM+DL+ groups, respectively.
The (o) symbol indicates the differences between obese and 12 months after surgery in each group; the (&) symbol indicates the differences between the obese in each group versus
the healthy group (DM−DL−); the (*) symbol indicates the differences between 12 and 6 months after surgery in each group; the (+) symbol indicates the differences between
DM−DL+ andDM+DL+; the (c) symbol indicates the differences between each time and obese group vs. control (lean) group. One symbol, p b 0.05; two symbols, p b 0.01; three sym-
bols, p b 0.001; ns, non-signiﬁcant.
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Table 2
LPL and HL activities and lipid parameters on morbidly obese liver patients in each group before and after bariatric surgery.
LIVER Anova-2, p value
Parameters Control (n = 7) Time DM−DL− (n = 9) DM−DL+ (n = 14) DM+DL+ (n = 6) Comorbidities effect Surgery effect
LPL (mU/g tissue) 36.8 ± 2.1 OB 78.7 ± 10.8c 97.4 ± 8.6cc 72.7 ± 17.6 ns ns
12 M 68.7 ± 17.3 67.7 ± 19.9 67.0 ± 10.3
p = ns p = 0.0295 p = ns
HL (mU/g tissue) 153.2 ± 9.3 OB 303.7 ± 26.3cc 253.2 ± 20.1c 231.5 ± 31.3c ns b0.0001
12 M 146.8 ± 16.7oo 142.6 ± 30.4o 115.5 ± 6.2o
p = 0.0036 p = 0.0081 p = 0.0430
Lipid (mg/g tissue) 24.0 ± 2.0 OB 201.1 ± 25.2ccc 178.1 ± 40.0ccc 244.4 ± 38.7c 0.0087 0.0001
12 M 27.5 ± 4.6ooo 74.0 ± 27.2o,c 69.9 ± 1.4o,c
p b 0.0001 p = ns p = 0.0065
Lipid (mg/mg DNA) 10.8 ± 2.0 OB 105.9 ± 18.7cc 102.7 ± 24.4c 148.0 ± 23.2ccc 0.0049 0.0017
12 M 19.7 ± 5.0oo 49.3 ± 16.9o 55.8 ± 9.7o,c
p = 0.0009 p = ns p = 0.0007
TAG (mg/mg DNA) 6.4 ± 1.6 OB 44.0 ± 8.6cc 40.0 ± 10.4 57.6 ± 9.8ccc 0.0219 0.0532 (ns)
12 M 9.6 ± 1.2oo 26.9 ± 10.2 34.7 ± 14.9
p = 0.0040 p = ns p = 0.0226
TC (mg/mg DNA) 0.44 ± 0.08 OB 12.5 ± 2.3c 13.3 ± 3.2c 19.0 ± 2.5cc 0.0095 b0.0001
12 M 2.2 ± 0.5o,c 3.5 ± 1.9o 2.4 ± 1.2oo
p = 0.0070 p = ns p = 0.0008
NEFA (mg/mg DNA) 0.23 ± 0.08 OB 6.8 ± 1.4cc 8.5 ± 1.0ccc 8.5 ± 1.2ccc b0.0001 ns
12 M 4.7 ± 1.1c 10.9 ± 0.3c 6.4 ± 0.9c
p = 0.0508 p = ns p = 0.0021
PL (mg/mg DNA) 2.43 ± 0.45 OB 42.59 ± 8.97cc 48.04 ± 12.25cc 79.35 ± 8.92ccc 0.0026 b0.0001
12 M 5.70 ± 1.52o 8.32 ± 2.63oo 9.05 ± 0.87ooo
p = 0.0143 p = 0.0475 p = ns
CRP (mg/mg DNA) 0.09 ± 0.05 OB 2.78 ± 0.51cc 6.02 ± 1.32c 3.44 ± 1.14 0.0396 0.0003
12 M 0.0 ± 0.0ooo 0.41 ± 0.19o 0.21 ± 0.21
p = 0.0003 p = 0.0108 p = 0.0419
The data are expressed as themeans± SEM. Abbreviations: LPL, lipoprotein lipase; HL, hepatic lipase; mU, nmol/min; PL, phospholipid. The (o) symbol indicates the differences between
obese and 6 or 12 months after surgery in each group; the (c) symbol indicates the differences between each time and obese group vs. control (lean) group. One symbol, p b 0.05; two
symbols, p b 0.01; three symbols, p b 0.001; ns, non-signiﬁcant.
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1. Genes with increased expression
Both the LPL and FAT/CD36 (Supplemental Table 1, and Fig. 2, top leftpanel) genes were over-expressed (2-fold compared with the control)
in theDM−DL+andDM+DL+groups. At one year after bariatric sur-
gery, LPL mRNA was detected in only 8 patients, including 3 in the
“healthy” group, 4 in the DM−DL+ group and 1 in the DL+DM+
group. Moreover, slight elevations in the liver HL, VLDLr (Supplemental
Table 1, and Fig. 1, top left panel) and SCARB1 (Supplemental Table 1,
and Fig. 1, middle right panel) expression levels were observed.
In the 3 obese groups, the TNFα (Supplemental Table 1, and Fig. 2,
bottom left panel) and PAI1 (Fig. 2, bottom right panel, and Supplemen-
tal Table 1) expression levels were between 40 and 100% greater than
the normal control levels. However, after surgery, TNFα expression
tended to decrease in the DL and DM groups compared with the obese
basal level, but its expression remained higher than that in the control
group. Additionally, PAI1 expression decreased by 30 to 50% compared
with the control group. Increased/decreased PAI1 gene expression in
the obese individuals pre- and post-surgery, respectively, corresponded
with the plasma PAI1 levels observed before and after surgery (Table 1).
The expression level of interleukin-6 (IL6, Supplemental Table 1) was
perfectly correlated with those of plasma PAI1 (r = 0.83, p b 0.0001)
and TNFα (r = 0.48, p = 0.0009) in the obese individuals.
2. Genes with reduced expression
The enzyme adipose triglyceride lipase (ATGL, Supplemental
Table 1) is also present in the liver. The ATGL mRNA level was decreased
by 30% in the healthy obese group compared with the control group,
and it was reduced by 23 and 18%, respectively, in the obese individuals
with comorbidities. After surgery, the ATGLmRNA level exhibited an in-
creasing trend, with restoration to the normal level. Liver apoB expres-
sion (Supplemental Table 1, and Fig. 1, bottom left panel) exhibited a
signiﬁcant decrease in the “healthy” individuals (p b 0.05 vs. control)
compared with the other 2 groups. At one year after surgery, a clearincrease in its expression was observed in the “healthy” and dyslipidae-
mic patients but not in the diabetic patients. The obese patients exhibit-
ed signiﬁcantly reduced LDLr (Supplemental Table 1, and Fig. 1, middle
left panel) expression comparedwith the controls (inmost cases, its ex-
pression decreased to less than 50% of the control level, both before and
after surgery; Fig. 1). Surgery tended to signiﬁcantly increase LDLr ex-
pression, and this increase was more marked in the “healthy” (p =
0.0004) and diabetic patients (p = 0.0201). The de novo cholesterol
synthesis regulatory enzyme HMG-CoA reductase (Supplemental
Table 1, and Fig. 1, top right panel) exhibited signiﬁcantly decreased ex-
pression in the “healthy” obese individuals (50% decrease, p b 0.01 vs.
control), but this reduction was not as notable in the other two obese
groups (Fig. 1). At one year after surgery, its expression tended to return
to the baseline level in the patients, with the exception of the dyslipid-
aemic obese patients. Additionally, the SCARB1, HMGCR, LDLr and, apoB
(Fig. 1) expression proﬁles were similar in all obese groups. Cholesterol
7 alpha-hydroxylase (CYP7A1) expression (Supplemental Table 1, and
Fig. 1, bottom right panel) was signiﬁcantly reduced in all three obese
groups compared with the control group (“healthy” obese =
p b 0.001; DM−DL+ p b 0.001; DM−DL+ p b 0.05; Fig. 1). At one
year after surgery, its level remained decreased by 50% in all groups.
In the 3 obese groups, PPARα and PGC1α expression (Supplemental
Table 1, and Fig. 2, middle right and left panel, respectively) was
reduced compared with the control group. After surgery, the PPARα
level increased to above the control level in all three MO groups. How-
ever, after surgery, the PGC1α level increased in the “healthy” MO
group compared with the other MO groups.
Fig. 3 summarises the liver gene expression in theMOpatients in the
DM+DL+ obese.4. Discussion
This study is theﬁrst to report that 1) hepatic lipid parameters inMO
patients change based on their comorbidities; 2) laboratory parameters
Table 3
Additional plasma parameters in morbidly obese patients in each group before and after bariatric surgery.
PLASMA Anova-2, p value
Parameters Control (n = 22) Time DM−DL− (n = 10) DM−DL+ (n = 15) DM+DL+ (n = 7) Comorbidities effect Surgery effect
AST (UI/L) 24.0 ± 1.4 OB 23.1 ± 2.0 20.8 ± 1.6 22.5 ± 2.4 ns 0.0002
1 M 38.8 ± 4.7o 33.2 ± 3.2oo 30.8 ± 4.9
6 M 20.3 ± 2.4** 21.3 ± 1.8** 17.2 ± 1.6*
12 M 22.2 ± 4.7* 21.8 ± 2.2** 18.7 ± 2.5
p = 0.0022 p = 0.0012 p = 0.0365
ALT (UI/L) 26.0 ± 1.5 OB 34.4 ± 4.9 29.9 ± 3.6 33.0 ± 5.3 ns b0.0001
1 M 64.6 ± 10.3o 51.5 ± 6.5oo 39.8 ± 9.4
6 M 22.5 ± 4.8*** 22.9 ± 2.6*** 15.9 ± 4.3*
12 M 20.3 ± 5.3*** 22.4 ± 2.8*** 17.9 ± 2.0
p = 0.0004 p b 0.0001 p = 0.0136
AST/ALT 0.94 ± 0.10 OB 0.77 ± 0.08 0.75 ± 0.06 0.72 ± 0.07 ns 0.0007
1 M 0.70 ± 0.09 0.68 ± 0.05 0.85 ± 0.14
6 M 1.07 ± 0.12 0.98 ± 0.06* 1.32 ± 0.28
12 M 1.23 ± 0.16* 1.02 ± 0.08** 1.05 ± 0.09
p = 00.112 p = 0011 p = ns
GGT (UI/L) 32.0 ± 1.8 OB 28.4 ± 2.5 47.4 ± 7.8 41.2 ± 8.2 ns 0.0008
1 M 32.1 ± 4.4 42.3 ± 8.3 25.5 ± 5.7
6 M 16.2 ± 1.8** 20.3 ± 3.2oo,* 15.5 ± 1.8o
12 M 17.4 ± 3.2 17.9 ± 2.3oo,* 14.1 ± 2.6oo
p = 0.0023 p = 0.0005 p = 0.0039
Alkalin phosphatase (UI/L) 58.2 ± 8.2 OB 76.7 ± 5.7 84.9 ± 5.6 68.8 ± 8.1 b0.0001 ns
1 M 79.0 ± 5.5 99.2 ± 6.8 72.3 ± 4.5
6 M 90.6 ± 9.3 93.1 ± 4.6 79.7 ± 6.5
12 M 91.8 ± 8.2 94.9 ± 5.4 75.9 ± 5.7
p = ns p = ns p = ns
Esteriﬁed bilirubin (mg/dL) 0.07 ± 0.00 OB 0.20 ± 0.03 0.21 ± 0.01 0.22 ± 0.03 b0.0001 ns
1 M 0.30 ± 0.04c 0.27 ± 0.02c 0.24 ± 0.03
6 M 0.30 ± 0.03c 0.23 ± 0.03 0.26 ± 0.02c
12 M 0.28 ± 0.03 0.27 ± 0.04c 0.31 ± 0.04cc
p = 0.0082 p = 0.0279 p = 0.0045
Total bilirubin (mg/dL) 0.51 ± 0.03 OB 0.44 ± 0.08 0.42 ± 0.04 0.47 ± 0.09 ns ns
1 M 0.62 ± 0.08 0.61 ± 0.06 0.55 ± 0.06
6 M 0.69 ± 0.09 0.55 ± 0.07 0.66 ± 0.07
12 M 0.66 ± 0.09 0.71 ± 0.15 0.74 ± 0.11
DM−DL− p = ns DM−DL+ p = ns DM+DL+ p = ns
Glycerol (mg/dL) 0.54 ± 0.11 OB 1.76 ± 0.14ccc 1.88 ± 0.15ccc 1.96 ± 0.16ccc b0.0001 0.0194
1 M 1.96 ± 0.25ccc 2.00 ± 0.14ccc 2.13 ± 0.23ccc
6 M 1.51 ± 0.13cc 1.60 ± 0.15ccc 1.35 ± 0.26
12 M 1.51 ± 0.19cc 1.49 ± 0.12ccc 1.51 ± 0.25c
p b 0.0001 p b 0.0001 p b 0.0001
NEFA (mM) 0.47 ± 0.04 OB 0.55 ± 0.07 0.60 ± 0.05 0.60 ± 0.09 0.0083 b0.0001
1 M 0.96 ± 0.10oo,ccc 1.06 ± 0.11ooo,ccc 0.84 ± 0.12cc
6 M 0.66 ± 0.10 0.65 ± 0.05*** 0.57 ± 0.06
12 M 0.42 ± 0.05*** 0.56 ± 0.07*** 0.55 ± 0.07
p b 0.0001 p b 0.0001 p = 0010
KB (mM) 0.08 ± 0.03 OB 0.08 ± 0.02 0.07 ± 0.02 0.05 ± 0.01 b0.0001 b0.0001
1 M 0.95 ± 0.21o,ccc 0.74 ± 0.17ooo,ccc 1.72 ± 0.48oo,ccc
6 M 0.39 ± 0.17* 0.16 ± 0.02o,cc 0.57 ± 0.06
12 M 0.11 ± 0.05* 0.11 ± 0.01** 0.11 ± 0.03
p = 0.0002 p b 0.0001 p = 0.0003
KB/NEFA 0.20 ± 0.08 OB 0.13 ± 0.03 0.10 ± 0.02 0.09 ± 0.02 b0.0001 b0.0001
1 M 0.96 ± 0.21o,ccc 0.71 ± 0.13ooo,ccc 1.77 ± 0.48c,o
6 M 0.45 ± 0.14 0.25 ± 0.02o,c 0.28 ± 0.06
12 M 0.22 ± 0.09 0.20 ± 0.03 0.22 ± 0.07
p = 0.0004 p b 0.0001 p = 0.0051
The data are expressed as themeans ± SEM. Abbreviations: AST, aspartate transaminase; ALT, alanine transaminase; AST:ALT, ratio of AST and ALT activities; GGT, γ-glutaryl transferase;
NEFA, non-esteriﬁed fatty acid; KB, ketone bodies; KB:NEFA, ratio of KB and NEFA; OB, 6 M and 12 M, obese, 6 and 12months after surgery in the DM−DL−, DM−DL+ and DM+DL+
groups, respectively. The (o) symbol indicates the differences between obese and 1, 6 or 12months after surgery in each group; the (*) symbol indicates the differences between 1month
and 6 or 12months after surgery in each group; the (c) symbol indicates the differences between each time or obese group versus control (lean) group. One symbol, p b 0.05; two symbols,
p b 0.01; three symbols, p b 0.001; ns, non-signiﬁcant.
59E. Pardina et al. / BBA Clinical 5 (2016) 54–65related to liver damage underestimate its severity; 3) liver damage is
worse in patients with dyslipidaemia or in those with diabetes and
dyslipidaemia; 4) cholesterol metabolism and NEFA levels are signif-
icantly altered in patientswith diabetes and dyslipidaemia; 5) bariat-
ric surgery typically restores various plasma and liver parameters,
but its effectiveness depends on the number of comorbidities pres-
ent; and 6) early changes (at onemonth) in hepatic parametersmea-
sured in the plasma after surgery can indicate systemic metabolic
modiﬁcations.4.1. Lipid metabolism
The three types of MO patients exhibited profoundly altered choles-
terol and lipid metabolism, especially when DL and DMwere present.
The diabetic obese individuals exhibited greater alterations in the
lipid parameters even though they had less total subcutaneous and vis-
ceral fat, and this ﬁnding was even observed in those with a reduced
BMI. The apoB:apoA-I atherogenesis ratio [38]was 0.47 in these individ-
uals compared with the “healthy” obese (0.42) and control individuals
Table 4
Histological scores from Brunt's index for the 24-paired liver biopsies before and after bariatric surgery.
BRUNT's index
DM−DL− DM−DL+ DM+ DL+ Anova-2, p value
0 1 2 3 0 1 2 3 0 1 2 3 Comorbidities effect Surgery effect
Feature before surgery Steatosis 0 5 2 1 0 6 3 2 0 1 2 2 ns
Balloon 3 1 4 0 5 4 2 0 2 1 1 1 ns
Lobinﬂ 0 7 1 0 1 10 0 0 0 4 1 0 ns
Portinﬂ 0 8 0 0 1 9 1 0 0 4 1 0 ns
Fibrosis 0 8 0 0 1 5 5 0 0 2 1 2 0.0395
Feature a year after surgery Steatosis 8 0 0 0 10 1 0 0 4 1 0 0 ns 0.0001
p = 0.0008 p = 0.0001 p = 0.0111
Balloon 8 0 0 0 10 1 0 0 5 0 0 0 ns 0.0021
p = 0.0148 p = 0.0107 p = ns
Lobinﬂ 6 2 0 0 5 6 0 0 3 2 0 0 ns 0.0004
p = 0.0062 p = 0.0379 p = 0.0161
Portinﬂ 5 3 0 0 1 10 0 0 0 5 0 0 0.0065 0.0280
p = 0.0112 p = ns p = ns
Fibrosis 4 4 0 0 3 5 3 0 1 2 1 1 ns 0.0159
p = 0.0331 p = ns p = ns
Each column in each group indicates the number of patients with each grade for the following categories: steatosis, hepatocyte ballooning (balloon), lobular inﬂammation (lobinﬂ), portal
inﬂammation (portinﬂ) and ﬁbrosis. The results of the two-way ANOVA (anova-2) are presented in the right columns. The p value under each group of patients and feature, in the lower
part of Table, is the result of compare before and a year after surgery.
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while this ratio was 3.90 in the “healthy” obese patients and 4.58 in
the diabetic patients. Thus,modiﬁcations in the plasma lipid parameters
could be attributed to liver impairment. These alterations in liver were
accompanied by larger hepatic cells (less DNA/g liver: 2.1 ± 0.1 mg/g
in DM−DL−, 1.9 ± 0.1 mg/g in DM−DL+ and, 1.7 ± 0.1 mg/g in
DM+DL+) and lipid-laden cells (see Table 2). The presence/increment
of LPL activity and the increment of HL activity could to contribute to
worsen the liver conditions (see below correlation between LPL and
HL and histological features) in morbid obese patients, as we could
seen by the concentration of total lipid, TAG, TC, NEFA and PL. In fact,
DM+DL+ are less able to recover after surgery, because those men-
tioned lipid were higher not only vs. DM−DL+, but also vs. healthy
and control patients. In our previous studies [12,13] and those of other
authors [40,41] it was mentioned this possibility.
4.2. Liver lipid accumulation
The increases in the liver lipid levelswere consistentwith the hepat-
ic steatosis observed in all patients, and theywere greater in the individ-
uals with DL or DL and DM.
The presence of excess lipids (especially NEFAs and lipids derived
fromTAGhydrolysis, DAGs and ceramides) results in liver inﬂammation
[39], and these increases were found to be correlated with elevatedTable 5
Scoring for the grade and stage of Non-alcoholic steatohepatitis (NASH) for the 24-paired liver
Score
DM−DL− DM−DL+
Before surgery 0 1 2 3 0 1 2
Grade 0 5 2 1 0 6 3
% 0 63 25 13 0 55 27
Stage 0 8 0 0 1 5 5
% 0 100 0 0 9.1 45 45
A year after surgery
Grade 8 0 0 0 10 1 0
% 100 0 0 0 91 9,1 0
p = 0.0008 p = 0.0001
Stage 4 4 0 0 3 5 3
% 50 50 0 0 27 45 27
p = 0.0112 p = ns
Each column in each group indicates the number of patients with each grade and stage with t
ANOVA (anova-2) are presented in the right columns. The p value under each group of patienttissue and plasma CRP levels and increased TNFα, IL6 and PAI1 expres-
sion. Recent evidence indicates that sphingolipid metabolism is altered
in obese individuals, suggesting a common pathway that links both ex-
cessive nutrient intake and inﬂammation with increasedmetabolic and
cardiovascular risks [42]. The liver phospholipid increases observed in
our patients, including the “healthy” and dyslipidaemic individuals
and especially the diabetic patients, were potentially related to in-
creased ceramide synthesis.
Uncontrolled lipolysis in the adipose tissue of obese individuals due
to peripheral IR provides an increased and continuous ﬂow of NEFAs to
the liver [43]. Our results are consistent with previous reports of elevat-
ed HSL activity [24] in both subcutaneous and visceral adipose tissues.
We observed increased liver NEFA levels that were potentially attribut-
ed to facilitated diffusion by FAT/CD36 carriers resulting from hydrolysis
of TAGs in QMs and of VLDL by LPL and the action of HL on HDL2. Phos-
pholipids are captured by HL, whereas cholesterol is captured via bind-
ing to lipoproteins or remnants containing apoE, whichmediates VLDLr,
HL and SCARB1 expression (LDLr is not involved, given its decreased ex-
pression). Therefore, the increased liver lipid levels in the diabetic MO
individuals can be explained by differences in plasma enzymatic activity
and gene expression.
Additionally, VLDLr overexpression and increased FAT/CD36 expres-
sion via TNFα liberation are strongly related to liver steatosis and in-
ﬂammation [44]. We propose that LPL in the liver could act as anotherbiopsies before and after bariatric surgery.
Anova-2, p value
DM+DL+ Comorbidities effect Surgery effect
3 0 1 2 3
2 0 1 2 2 ns
18 0 20 40 40
0 0 2 1 2 0.0395
0 0 40 20 40
0 4 1 0 0 ns b0.0001
0 80 20 0 0
p = 0.0111
0 1 2 1 1 ns 0.0159
0 20 40 20 20
p = ns
he corresponding percentages before and a year after surgery. The results of the two-way
s and feature, in the lower part of Table, is the result of compare before and after surgery.
Fig. 1.VLDLr,HMGCR, LDLr, SCARB1, apoB and, CYP7a1 expression in the liver. RelativemRNA levelswere evaluated using theΔΔCtmethod. The results are expressed as themeans± SEM
vs. 100% in the control group (dotted line). For gene abbreviations, see Supplemental Table 1. The DM−DL− group is presented as white bars. The DM−DL+ group is depicted as grey
bars, and the DM+DL+ group is presented as black bars. Two-way ANOVA (anova-2) results are presented in left corner in each graph; the ﬁrst number is the result of the comorbidity
effects, and the second number represents the surgery effects. Statistical results in each group vs. the control are presented as thewhite square in each group of the bar. Abbreviations: OB
and 12 M, obese, and 12 months after surgery in the DM−DL−, DM−DL+ and DM+DL+ groups, respectively; a.u., arbitrary units. The (o) symbol indicates the differences between
obese and 12months after surgery in each group; the (c) symbol indicates the differences between each time vs. the control (lean) group. One symbol, p b 0.05; two symbols, p b 0.01; ns,
non-signiﬁcant.
61E. Pardina et al. / BBA Clinical 5 (2016) 54–65factor to promote lipid accumulation and the subsequent onset/pro-
gression of NAFLD. In fact, TNFα promotes LPL liver expression [45].
Moreover, LPL overexpression inmice causes hepatic steatosis and insu-
lin resistance [40]. LPL mRNA has been reported to be present in the
human fatty livers of IR subjects [12]. However, the correlation between
LPL expression and its local enzymatic activity has not been elucidated.
Our results are consistent with previous reports suggesting that
NEFAs in hepatocytes can be oxidised or converted to KBs [46], especial-
ly during the ﬁrst month after surgery. When the liver is no longer
steatotic, e.g., after surgery, LPL expression is not detected. Consequent-
ly, increased liver LPL expression could act as a protectivemechanismbyredirecting lipid accumulation to the liver, ameliorating the effects of
plasma hyperlipidaemia on other tissues.
4.3. Lipid metabolite destinations within the liver
Hepatic steatosis could develop through any combination of in-
creased liver free fatty acid (FFA) uptake and storage as TAG, increased
de novo lipogenesis, decreased fatty acid oxidation, and decreased se-
cretion of TAG as VLDL [47–49]. Evidence from Morris et al. [50] and
others [51,52] suggests that elevated mitochondrial number and func-
tion increase fatty acid oxidation, which may play a protective role by
Fig. 2. FAT/CD36, CPT11α, PPARα PPARα, TNFα and, PAI1 expression in the liver. RelativemRNA levelswere evaluatedusing theΔΔCtmethod. The results are expressed as themeans±SEM
vs. 100% in the control group (dotted line). For gene abbreviations, see Supplemental Table 1. The DM−DL− group is presented as white bars. The DM−DL+ group is depicted as grey
bars, and the DM+DL+ group is presented as black bars. Two-way ANOVA (anova-2) results are presented in left corner in each graph; the ﬁrst number is the result of the comorbidities
effects, and the second number represents the surgical effects. Statistical results in each group vs. control are presented as the white square in each group of bar. Abbreviations: OB and
12 M, obese, 6 and 12 months after surgery in the DM−DL−, DM−DL+ and DM+DL+ groups, respectively; a.u., arbitrary units. The (o) symbol indicates the differences between
obese and 12 months after surgery in each group; the (c) symbol indicates the differences between each time vs. control (lean) group. One symbol, p b 0.05; two symbols, p b 0.01;
three symbols, p b 0.001; ns, non-signiﬁcant.
62 E. Pardina et al. / BBA Clinical 5 (2016) 54–65reducing hepatic TAG accumulation. However, recently, has been de-
scribed that despite similar mitochondrial content, obese humans
with or without NAFLD had 4.3- to 5.0-fold higher maximal respiration
rates in isolated mitochondria than lean persons. NASH patients
featured highermitochondrialmass, but 31%–40% lowermaximal respi-
ration, which associated with greater hepatic insulin resistance, mito-
chondrial uncoupling, and leaking activity [53]. On the other hand,
some authors described Increased VLDL-TG in type 2 diabetic men is
caused by greater VLDL-TG secretion and less so by lower VLDL-TG
clearance [54]. In addition, with liver fatty acid uptake, gene expression
of hepatic lipase (HL) and liver lipoprotein lipase (LPL) are higher inobese subjects with NAFLD than subjects without NAFLD, suggesting
that FFA released from lipolysis of circulating TAG also contribute to
hepatocellular FFA accumulation and steatosis [13,41,49].
NEFA β-oxidation was decreased in the patients with NAFLD, possi-
bly due to inhibition caused by the effects of increased malonyl-CoA on
CPT1a [55]; however, this hypothesis was not supported by our results.
Alternatively, increased UCP2 [56] has been reported to improve the
elimination of excess NEFAs, and it was found to be slightly increased
in the MO individuals in our study. Moreover, the direction of acetyl-
CoA towards ketogenesis was highly increased in our patients, mainly
after the ﬁfth month post-surgery, when a great quantity of fat was
Fig. 3. Scheme of liver gene expression in the DM+DL+ obese group. For gene abbreviations, see Supplemental Table 1. The upward arrow by a gene's name indicates increased
expression, whereas dotted downward arrows indicate decreased expression for comparisons between the DM+DL+ obese group vs. control (see Supplemental Table 1). The up and
down arrows (CPT1a) indicate no difference vs. control. The wide upward arrows by the KB, NEFA, PL, TAG and EC compounds indicate that these compounds are increased in the
liver (see Results section in the text). Other abbreviations: β-oxidation (β-ox); acetyl CoA (Ac-CoA); Krebs cycle (KC); respiratory chain/oxidative phosphorylation (RC/OF); adenosine
tri-phosphate (ATP); chylomicron or remnants (QM or rQM); very low density lipoproteins or remnants (VLDL or rVLDL); high, intermediate and low density lipoproteins (HDL2, IDL
and LDL, respectively); very low and low density lipoprotein receptor (VLDLr and LDLr).
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cal because themetabolic pathway for cholesterol synthesis or elimina-
tion via synthesis of bile salts was inhibited by decreased HMGCR
expression, possibly due to the presence of excess cholesterol and
CPY7a1 expression in the liver, as we have observed.
Nine of the 19 studied genes (ATGL, LDLr, apoB, HMGCR, CYP7A1,
PPARα, PGC1α, iNOS2 and eNOS3) exhibited decreased expression in
the three types of MO individuals. This expression pattern was more
pronounced in the “unhealthy”MO patients, especially in the presence
of DM.
The plasma CRP and PAI1 levels are not useful for identifying these
changes considering that they were very similar in all three groups of
MO patients. Moreover, the hepatic CRP level, as well as parameters
commonly used to determine liver damage, such as AST, ALT, AST/ALT
(a ratio of lower than 1 has been proposed by some authors [57] to be
indicative of liver pathology), GGT, and alkalinephosphatase,was corre-
latedwith the severity of liver damage in the obese diabetics. Converse-
ly, other studies have suggested that the TAG, HDL, AST and ALT levels
(but not the TNFα, leptin or adiponectin level) are useful for differenti-
ating between severely obese individuals without NAFLD and those
with NASH [51]. Plasma PAI1 protein and liver PAI1 expression was
found to be strongly correlated with inﬂammation in the 3 groups of
MO patients and to decrease sharply at 12 months after surgery. There-
fore, theDM+DL+patients exhibited a positive correlation (r=0.953;
p= 0.012) between PAI1 expression and liver inﬂammation. Neverthe-
less, this correlation was not observed in the other obese groups. From
our point of view, the hepatic lipase (HL) and liver lipoprotein lipase
(LPL) analysis could cover a large part of the histological features that
we can be observed in a liver biopsy. For example, the LPL correlated
with liver steatosis (r = 0.921; p = 0.027) in “healthy” patients
(DM−DL−) and, with liver ballonization (r = 0.953; p = 0.047) and
ﬁbrosis (r = 0.991; p = 0.009) in diabetic and dyslipidaemic group
(DM+DL+). While HL correlated with portal inﬂammation (r =
0.713; p = 0.021) in dyslipidaemic group (DM−DL+).
4.4. Liver lipid levels and bariatric surgery
The metabolic effects of bariatric surgery were more pronounced in
the “healthy” patients compared with the dyslipidaemic or diabeticpatients. At one year after bariatric surgery, recovery of many of the
previously altered biochemical parameters was observed in both the
plasma and liver samples.
Consistent with previous reports [13], we observed drastic reduc-
tions in the TAG and TC levels in both the liver and plasma following
bariatric surgery; however, these reductions were more marked in the
present study compared with other reports [58]. These reductions in
hepatocyte TAG levels were accompanied by reduced lipid levels
(NEFAs and PLs). Additionally, the lipid per DNA (or per liver cell)
level decreased by 81% at one year after bariatric surgery in the
“healthy” obese individuals and by 50 and 60% in the DM−DL+ and
DM+DL+ patients, respectively. After surgery, a trend of normalisa-
tion of LDLr expression (as has been observed by other authors [59] in
monocytes collected from individuals after completing a weight reduc-
tion programme), apoB, HMGCR, PPARα and PGC1α as well as the re-
duced expression of CYP7A1, FAT/CD36, IL6 and PAI1. However, the
reductions in the TAG levels occurred in the absence of concomitant
decreases in the plasma NEFA levels (without reduced liver uptake of
NEFAs). In contrast, LPL activity and expression in the liver was signiﬁ-
cantly reduced after bariatric surgery, consistent with the decrease in
hepatic TAGs. We reported good individual correlation between liver
LPL activity and the degree of liver damage, both before and after bariat-
ric surgery [12].
The mechanism(s) underlying the relationship between hepatic
steatosis and insulin resistance remain unknown. However, other
factors associated with steatosis, such as inﬂammation, circulating
adipokines, endoplasmic reticulum stress, and unidentiﬁed lipidmetab-
olites, can affect insulin sensitivity but are not necessarily directly corre-
lated with intrahepatic triglyceride levels [48]. This observation could
explain why the insulin resistance observed in our patients was de-
creased by up to 57% at only 1 month after surgery, whereas the FFA,
glycerol and KB levels exhibited peak plasma concentrations at this
time point. The CRP level after one month remained similar to that
observed in the obese individuals, but the leptin and PAI1 levels were
decreased by 36%. These results suggest that IR is not necessarily associ-
ated with the plasma FFA concentration, as other authors have sug-
gested [60].
In conclusion, we observed an increase in the hepatic lipid level and
increased expression of genes involved in lipid accumulation in the
64 E. Pardina et al. / BBA Clinical 5 (2016) 54–65“healthy”MO patients and MO dyslipidaemic patients with or without
diabetes; however, only a limited number of individualswere examined
in this study. Increased LPL and HL activities in the livers of obese indi-
viduals, together with the increased expression of key receptors, such
as FAT/CD36, could contribute to the accumulation of liver fat and subse-
quent steatosis. Thus, quantitativemeasurements of liver LPL andHL ac-
tivities and fat content are important for evaluating the roles of liver fat
in insulin resistance, obesity, and type 2 diabetes and for correctly diag-
nosing and reducing the severity of liver damage.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2015.12.002.
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